Literature DB >> 16140921

Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy.

Steve Broomfield1, Andrew Currie, Robbert G van der Most, Matthew Brown, Ivonne van Bruggen, Bruce W S Robinson, Richard A Lake.   

Abstract

Resection alone is rarely curative for advanced tumors, but the outcome generally improves with adjuvant therapy. We have previously shown that a combination of traditional chemotherapy (gemcitabine) and immunotherapy (anti-CD40/FGK-45) without surgery is synergistic and can lead to long-term cure when applied to small tumors. Such cured animals have immunologic memory and are protected from rechallenge. Here we investigate the effectiveness of combination chemotherapy and immunotherapy after partial or complete surgical debulking of large tumors. We found that complete resection followed by combination chemotherapy/immunotherapy led to a high rate of cure (>80%) but failed to induce a long-term, tumor-specific memory. Partial debulking followed by combination therapy elicited the same proportion of cured animals but in contrast to complete resection, a memory response was invoked. We postulate that chemotherapy induced apoptosis of the residual tumor cells following incomplete resection is absolutely required for the induction of long-term immunologic memory.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140921     DOI: 10.1158/0008-5472.CAN-05-0328

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes.

Authors:  Scott M J Cornwall; Matthew Wikstrom; Arthur W Musk; John Alvarez; Anna K Nowak; Delia J Nelson
Journal:  Oncoimmunology       Date:  2015-08-31       Impact factor: 8.110

Review 2.  Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.

Authors:  Adam J Bograd; Kei Suzuki; Eva Vertes; Christos Colovos; Eduardo A Morales; Michel Sadelain; Prasad S Adusumilli
Journal:  Cancer Immunol Immunother       Date:  2011-09-13       Impact factor: 6.968

3.  Murine mesothelioma induces locally-proliferating IL-10(+)TNF-α(+)CD206(-)CX3CR1(+) M3 macrophages that can be selectively depleted by chemotherapy or immunotherapy.

Authors:  Connie Jackaman; Teong L Yeoh; Manyual L Acuil; Joanne K Gardner; Delia J Nelson
Journal:  Oncoimmunology       Date:  2016-04-22       Impact factor: 8.110

4.  Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.

Authors:  Jay Friedman; Ellen C Moore; Paul Zolkind; Yvette Robbins; Paul E Clavijo; Lilian Sun; Sarah Greene; Megan V Morisada; Wojciech K Mydlarz; Nicole Schmitt; James W Hodge; Hans Schreiber; Carter Van Waes; Ravindra Uppaluri; Clint Allen
Journal:  Clin Cancer Res       Date:  2019-10-23       Impact factor: 12.531

5.  A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation.

Authors:  Jarrod D Predina; Brendan Judy; Zvi G Fridlender; Louis A Aliperti; Brian Madajewski; Veena Kapoor; Guanjun Cheng; Jon Quatromoni; Olugbenga Okusanya; Sunil Singhal
Journal:  Cancer Biol Ther       Date:  2012-05-23       Impact factor: 4.742

Review 6.  Redirecting the immune response: role of adoptive T cell therapy.

Authors:  Anna Mondino; Valérie Dardalhon; Rodrigo Hess Michelini; Severine Loisel-Meyer; Naomi Taylor
Journal:  Hum Gene Ther       Date:  2010-05       Impact factor: 5.695

Review 7.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Chemo-immunotherapy mediates durable cure of orthotopic KrasG12D/p53-/- pancreatic ductal adenocarcinoma.

Authors:  Vanaja Konduri; Dali Li; Matthew M Halpert; Dan Liang; Zhengdong Liang; Yunyu Chen; William E Fisher; Silke Paust; Jonathan M Levitt; Qizhi Cathy Yao; William K Decker
Journal:  Oncoimmunology       Date:  2016-07-22       Impact factor: 8.110

9.  Herbal compound "Songyou Yin" reinforced the ability of interferon-alfa to inhibit the enhanced metastatic potential induced by palliative resection of hepatocellular carcinoma in nude mice.

Authors:  Xiu-Yan Huang; Zi-Li Huang; Lu Wang; Yong-Hua Xu; Xin-Yu Huang; Kai-Xing Ai; Qi Zheng; Zhao-You Tang
Journal:  BMC Cancer       Date:  2010-10-25       Impact factor: 4.430

10.  Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.

Authors:  C Bauer; F Bauernfeind; A Sterzik; M Orban; M Schnurr; H A Lehr; S Endres; A Eigler; M Dauer
Journal:  Gut       Date:  2007-03-29       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.